Aktienanalyse zu Xencor Inc (XNCR)XNCRXencor Inc

Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases. It has more than 20 candidates engineered with its XmAb technology that are in clinical development, and multiple XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly-owned development candidates include XmAb942, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Its clinical-stage drug candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, Xpro1595, Obexelimab, and Novartis XmAb, an undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of efbalropendekin alfa (XmAb306/RG6323). Its Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Xencor Inc is currently not a strong buy due to its low RSI of 31.176, indicating oversold conditions, and a significant forward P/E ratio of 68.03, suggesting high valuation expectations. However, the stock has shown a year-to-date change of +53.15%, indicating strong performance over the year. The main risk is the recent 5-day change of -7.23%, which reflects downward momentum in the short term.

5 analysts cover XNCR: 4 rate it Buy, 1 Hold and 0 Sell. The average price target is 26.25.